57
Views
14
CrossRef citations to date
0
Altmetric
Original Articles

Comparison of Prognostic Importance of Latest CD4+ Cell Count and HIV RNA Levels in Patients with Advanced HIV Infection on Highly Active Antiretroviral Therapy

, , , , , & show all
Pages 127-135 | Published online: 02 Feb 2015

REFERENCES

  • Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167–1170.
  • CASCADE Collaboration. Short-term risk of AIDS accord-ing to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. AIDS. 2004;18:51–58.
  • Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.
  • Lederberger B, Egger M, Erard V, et al. AIDS-related op-portunistic illnesses occurring after initiation of potent antiretroviral therapy. The Swiss HIV Cohort Study. JAMA. 1999;282:2220–2226.
  • Miller V, Staszewski S, Nisius G, et al. Risk of new AIDS diseases in people on triple therapy [letter]. Lancet. 1999;353:463.
  • Binquet C, Chene G, Jacqmin-Gadda H, et al. Modeling changes in CD4+-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996–1997. Am J EpidemioL 2001153: 386–393.
  • Hogg RS, Yip B, Chan KJ, et al. Rates of disease progres-sion by baseline CD4+ cell count and viral load after initiat-ing triple-drug therapy. JAMA. 2001;286:2568–2577.
  • Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4+ T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 2001;15:2251–2257.
  • van Sighem Al, van de Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS. 2003;17:2259–2260.
  • Miller V, Sabin CA, Phillips AN, et al. The impact of pro-tease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4+ and viral load. AIDS. 2000;14:2129–2136.
  • Kaplan JE, Hanson DL, Jones JL, Dworkin MS, and the Adult and Adolescent Spectrum of HIV Disease Project Investigators. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adoles-cents. AIDS. 2001;15:1831–1836.
  • Lewden C, Raffi F, Cuzin L, et al. Factors associated with mortality in human immunodeficiency virus type l-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 Study). J Infect Dis. 2002;186:710–714.
  • Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prog-nostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA Study. J Infect Dis. 2002;185:178–187.
  • Miller V, Phillips AN, Clotet B, et al. Association of virus load, CD4 cell count, and treatment with clinical progres-sion in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis. 2002;186:189–197.
  • The Antiretroviral Therapy (ART) Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679–686.
  • Anastos K, Barrón Y, Cohen MH, et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med. 2004;140:256–264.
  • Perez G, MacArthur RD, Walmsley S, et al. A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clin Trials. 2004;5:7–18.
  • Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin MicrobioL 1994;32:292–300.
  • Green LA, Rhame FS, Price RW, et al. Experience with a cross-study endpoint review committee for AIDS clinical trials. AIDS. 1998;12:1983–1990.
  • Cox DR. Regression models and life-tables. J Roy Stat Soc Ser B. 1972;34:187–220.
  • Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet. 2000; 356:291–296.
  • The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virologic failure to all three antiretroviral-drug classes. Lancet. 2004;364:51–62.
  • HIV Surrogate Marker Collaborative Group. Human immu-nodeficiency virus type 1 RNA level and CD4+ cell count as prognostic markers and surrogate end points: a meta-analysis. AIDS Res Hum Retro viruses. 2000;16:1123–1133.
  • Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286:2597–2599.
  • Hennessey KA, Giorgi JV, Kaplan AH, et al. AIDS onset at high CD4+ cell levels is associated with high viral load. AIDS Res Hum Retroviruses. 2000;16:103–107.
  • Lederman MM, Valdez H. Immune restoration with antiretroviral therapies. Implications for clinical manage-ment. JAMA. 2000;284:223–228.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.